( etic mechanismsco-operate to silence k...)Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting,Health

Pharmion has three epigenetic products in its portfolio, including Vidaza(R) (azacitidine for injection), MGCD0103 and oral Azacitidine. Pharmion currently markets Vidaza, its parenteral formulation of Azacitidine, in the U.S. and several additional countries for the treatment of patients with MDS. Abstracts presented at this year's ASCO meeting will address the pharmacokinetics of oral Azacitidine administration, and report data from studies investigating Vidaza's utility in MDS, including alternative dosing schedules and in the treatment of MDS patients with marrow fibrosis.

Additionally, accepted abstracts will investigate the use of Vidaza as part of combination treatment regimens with other epigenetic therapies, including interim results from an ongoing study with MGCD0103, for the treatment of high-risk MDS and acute myeloid leukemia (AML), and in combination with valproic acid in advanced solid tumors.

An oral presentation on a study of MGCD0103 in relapsed/refractory Hodgkin's lymphoma will be presented during ASCO, as will a poster on the use of MGCD0103 as a single agent in patients with MDS or leukemias. Pharmion has a licensing and collaboration agreement with MethylGene for MGCD0103, as well as MethylGene's pipeline of second-generation HDAC inhibitor compounds for oncology indications.

Data from a first-line study evaluating the addition of Thalidomide to the standard of care for elderly multiple myeloma patients will be the subject of an oral presentation at the 2007 ASCO meeting, where a total of three oral presentations and six posters on Thalidomide studies will be presented. Data from the oral presentation reinforce the substantial body of
'"/>